Charles River Laboratories International, Inc. (NYSE:CRL) Position Lessened by Riverbridge Partners LLC

Riverbridge Partners LLC lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 10.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 239,388 shares of the medical research company’s stock after selling 27,059 shares during the quarter. Riverbridge Partners LLC owned approximately 0.47% of Charles River Laboratories International worth $44,191,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP grew its stake in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after buying an additional 3,738,018 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after acquiring an additional 509,163 shares during the last quarter. Earnest Partners LLC grew its position in Charles River Laboratories International by 12.4% in the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after acquiring an additional 110,725 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Charles River Laboratories International by 73.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 239,913 shares of the medical research company’s stock worth $49,561,000 after purchasing an additional 101,732 shares during the last quarter. Finally, Mizuho Securities USA LLC raised its holdings in shares of Charles River Laboratories International by 2,336.4% during the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock valued at $19,081,000 after purchasing an additional 92,895 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $168.27 on Thursday. The company’s fifty day moving average is $187.81 and its two-hundred day moving average is $197.72. Charles River Laboratories International, Inc. has a 52-week low of $160.85 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The firm has a market capitalization of $8.61 billion, a price-to-earnings ratio of 21.06, a P/E/G ratio of 5.97 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the business earned $2.72 earnings per share. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price objective for the company. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Bank of America decreased their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price target for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $209.00.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).